Temporal Trends of Subsequent Malignant Neoplasms in Childhood Cancer Survivors and the Impact of Treatment Changes: A DCCSS-LATER Study
Clicks: 2
ID: 317105
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #321 of 333 articles by views in JNCI Journal of the National Cancer Institute
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 333 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background The growing population of childhood cancer survivors faces an elevated risk of developing subsequent malignant neoplasms (SMNs). Over the past decades, childhood cancer treatments have evolved. Although reductions in radiation dose have been shown to lower SMN risk, the impact of changes in chemotherapy remains unclear. We evaluated whether treatment changes have affected SMN risk over time and examined treatment-related risk factors. Methods We included 10,612 five-year survivors from the Dutch Childhood Cancer Survivor Study (DCCSS)-LATER cohort (1963 to 2014). Multivariable Cox proportional hazard regression was used to estimate SMN risks, and to evaluate effects of treatment changes over time. Results After a median follow-up of 20.4 years, 493 survivors developed an SMN. Overall, the risk for SMN declined over period of diagnosis (p-trend 0.04). The decline in SMN risk was primarily associated with a decreased use of radiotherapy (p-trend after radiotherapy adjustment : 0.51). Chemotherapy seemed to have the opposite effect, mainly due to the use of anthracyclines and/or epipodophyllotoxins (p-trend after chemotherapy adjustment:<0.001). Survivors treated with anthracyclines (HR : 1.3, 95%CI : 1.0 to 1.6), epipodophyllotoxins (HR : 1.3,95%CI : 1.0 to 1.7) or radiotherapy (HR : 2.3, 95%CI : 1.9-2.8) had significantly increased risks of SMN. Conclusions While reductions in radiotherapy have lowered SMN risk throughout periods of diagnosis, the increased use of chemotherapy, especially anthracyclines and epipodophyllotoxins, increased SMN risk. Furthermore, survivors treated with radiotherapy, anthracyclines, or epipodophyllotoxins have an elevated risk of any SMN. This highlights the importance of continued optimization of treatment protocols, eg through chemotherapy dose reduction, to balance treatment efficacy with long-term health risks and to better identify survivors at risk.
| Reference Key |
openalex_W7164560205
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Aimée S R Westerveld, Helena J H van der Pal, Joyce Wilbers, Andrica C H de Vries, Marloes Louwerens, Maria M W Koopman, Judith L. Kok, Marry M. van den Heuvel‐Eibrink, Margriet van der Heiden - van der Loo, Dorine Bresters, Max M van Noesel, Eelco W. Hoving, Jan L C Loeffen, Hanneke M. van Santen, F Van Leeuwen, Otto Visser, Geert O. Janssens, Cecile M Ronckers, L. C.M. Kremer, Jop C. Teepen |
| Journal | JNCI Journal of the National Cancer Institute |
| Year | 2026 |
| DOI |
10.1093/jnci/djag169
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.